Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer’s disease
Authors:
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (9) , 127097
Abstract
No abstract availableKeywords
Funding Information
- Jiangsu Provincial Department of Education
This publication has 25 references indexed in Scilit:
- Phosphodiesterases in neurodegenerative disordersIUBMB Life, 2012
- Alzheimer's diseaseThe Lancet, 2006
- Anti-inflammatory principles from the fruits ofEvodia rutaecarpa and their cellular action mechanismsArchives of Pharmacal Research, 2006
- The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's diseaseHealth Technology Assessment, 2006
- Facile zeolite induced Fischer-indole synthesis: a new approach to bioactive natural product rutaecarpineTetrahedron, 2004
- The Cardioprotection of Rutaecarpine is Mediated by Endogenous Calcitonin Related-Gene Peptide Through Activation of Vanilloid Receptors in Guinea-Pig HeartsPlanta Medica, 2002
- Substituted Pyrazolopyridines as Potent and Selective PDE5 Inhibitors: Potential Agents for Treatment of Erectile DysfunctionJournal of Medicinal Chemistry, 2001
- 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: Synthesis and Inhibitory Activity toward Phosphodiesterase 5Journal of Medicinal Chemistry, 2000
- Sildenafil (Viagra) and OphthalmologySurvey of Ophthalmology, 1999
- Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effects of 7-nitroindazole and zaprinastEuropean Journal of Pharmacology, 1997